Transcriptomic Analyses of Exercise Training in Alzheimer's Disease Cerebral Cortex. 2023

Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan.

Research reported exercise could reduce Alzheimer's disease (AD) symptoms in human and animals. However, the molecular mechanism of exercise training via transcriptomic analysis was unclear especially in AD in the cortex area. Investigate potential significant pathways in the cortex area that were affected by exercise during AD. RNA-seq analysis, differential expressed genes, functional enrichment analysis, and GSOAP clustering analysis were performed in the isolated cerebral cortex from eight 3xTg AD mice (12 weeks old) randomly and equally divided into control (AD) and exercise training (AD-EX) group. Swimming exercise training in AD-EX group was conducted 30 min/day for 1 month. There were 412 genes significant differentially expressed in AD-EX group compared to AD group. Top 10 upregulated genes in AD-EX group against AD group mostly correlated with neuroinflammation, while top 10 downregulated genes mostly had connection with vascularization, membrane transport, learning memory, and chemokine signal. Pathway analysis revealed the upregulated interferon alpha beta signaling in AD-EX had association with cytokines delivery in microglia cells compared to AD and top 10 upregulated genes involved in interferon alpha beta were Usp18, Isg15, Mx1, Mx2, Stat1, Oas1a, and Irf9; The downregulated extracellular matrix organization in AD-EX had correlation with Aβ and neuron cells interaction and Vtn was one of the top 10 downregulated genes involved in this pathway. Exercise training influenced 3xTg mice cortex through interferon alpha beta signaling upregulation and extracellular matrix organization downregulation based on transcriptomics analysis.

UI MeSH Term Description Entries
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon
D043222 Ubiquitin Thiolesterase A thioester hydrolase which acts on esters formed between thiols such as DITHIOTHREITOL or GLUTATHIONE and the C-terminal glycine residue of UBIQUITIN. Neuron Cytoplasmic Protein 9.5,PARK5 Protein,Parkinson Disease 5 Protein,UCHL1 Protein,Ubiquitin C-Terminal Esterase,Ubiquitin C-Terminal Hydrolase,Ubiquitin Carboxy-Terminal Esterase,Ubiquitin Carboxy-Terminal Hydrolase,Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1,Uch-L1 Protein,C-Terminal Esterase, Ubiquitin,C-Terminal Hydrolase, Ubiquitin,Carboxy-Terminal Esterase, Ubiquitin,Carboxy-Terminal Hydrolase, Ubiquitin,Esterase, Ubiquitin C-Terminal,Esterase, Ubiquitin Carboxy-Terminal,Hydrolase, Ubiquitin C-Terminal,Hydrolase, Ubiquitin Carboxy-Terminal,Thiolesterase, Ubiquitin,Ubiquitin C Terminal Esterase,Ubiquitin C Terminal Hydrolase,Ubiquitin Carboxy Terminal Esterase,Ubiquitin Carboxy Terminal Hydrolase,Ubiquitin Carboxyl Terminal Hydrolase Isozyme L1,Uch L1 Protein
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
May 2023, Life (Basel, Switzerland),
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
July 1982, Lancet (London, England),
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
January 1964, Transactions of the American Neurological Association,
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
January 1987, Acta neuropathologica,
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
May 1991, Neurology,
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
January 1996, Biological psychiatry,
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
January 1996, Biological psychiatry,
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
December 1996, Acta neuropathologica,
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
January 2020, Frontiers in bioengineering and biotechnology,
Michael Anekson Widjaya, and Yu-Jung Cheng, and Yu-Min Kuo, and Chia-Hsin Liu, and Wei-Chung Cheng, and Shin-Da Lee
August 2023, Advanced science (Weinheim, Baden-Wurttemberg, Germany),
Copied contents to your clipboard!